docetaxel anhydrous has been researched along with etoposide in 128 studies
| Studies (docetaxel anhydrous) | Trials (docetaxel anhydrous) | Recent Studies (post-2010) (docetaxel anhydrous) | Studies (etoposide) | Trials (etoposide) | Recent Studies (post-2010) (etoposide) |
|---|---|---|---|---|---|
| 12,110 | 3,216 | 6,920 | 18,306 | 3,693 | 4,900 |
| Protein | Taxonomy | docetaxel anhydrous (IC50) | etoposide (IC50) |
|---|---|---|---|
| nuclear receptor coactivator 1 isoform 1 [Homo sapiens] | Homo sapiens (human) | 1.153 | |
| nuclear receptor coactivator 3 isoform a | Homo sapiens (human) | 1.4284 | |
| Polyunsaturated fatty acid lipoxygenase ALOX15 | Oryctolagus cuniculus (rabbit) | 3.187 | |
| Caspase-3 | Homo sapiens (human) | 1 | |
| DNA topoisomerase 2-beta | Homo sapiens (human) | 0.4299 | |
| Solute carrier organic anion transporter family member 1B3 | Homo sapiens (human) | 4.18 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 8 (6.25) | 18.2507 |
| 2000's | 61 (47.66) | 29.6817 |
| 2010's | 49 (38.28) | 24.3611 |
| 2020's | 10 (7.81) | 2.80 |
| Authors | Studies |
|---|---|
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Alim, Z; Beydemir, Ş | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Cai, B; Cui, CB; Li, CW; Wang, N; Xu, LL; Zhu, HJ | 1 |
| Abdel-Moty, SG; Andrei, G; Hayallah, AM; Mohammed, AF; Simons, C; Snoeck, R | 1 |
| Daelemans, D; Groaz, E; Herdewijn, P; Li, Q; Persoons, L | 1 |
| Abel, G; Kelland, LR | 1 |
| Hatae, M; Hokanishi, H; Kume, H; Maeda, Y; Nakagawa, S; Onishi, Y | 1 |
| Linsenmeyer, ME; Millward, MJ; Rischin, D; Urch, ME; Webster, LK; Woodcock, DM | 1 |
| Negoro, S | 1 |
| Battaglia, A; Bonanno, G; Fattorossi, A; Leone, G; Mancuso, S; Menichella, G; Panici, PB; Perillo, A; Pierelli, L; Scambia, G | 1 |
| Ajani, JA | 1 |
| Armand, JP; Couteau, C | 1 |
| Inoue, H; Kim, R; Ohi, Y; Toge, T | 1 |
| Bianco, AR; Caputo, R; Ciardiello, F; De Laurentiis, M; De Placido, S; Pomatico, G; Tortora, G | 1 |
| Bamias, A; Katsimbri, P; Pavlidis, N | 1 |
| Alderson, PO; Cannon, P; Katz, J; Kline, RP; Petrylak, DP; Szabolcs, M; Weisfeldt, ML; Wu, EX | 1 |
| Bonomi, P; Shirazi, W | 1 |
| Belani, CP; Calvo, AR | 1 |
| Ratain, MJ; Sawyer, M | 1 |
| Hudes, GR; Obasaju, C | 1 |
| Fujita, S; Hasegawa, T; Ikeda, A; Kaneshiro, E; Katakami, N; Nishimura, T; Nishio, C; Okazaki, M; Umeda, B | 1 |
| Boccieri, MG; Bruschi, G; Lo Re, G; Saracchini, S; Toffoli, G; Tumolo, S | 1 |
| Hisada, T; Ito, T; Masuda, S; Mochida, A; Morinari, H; Nakahara, K; Nishi, K; Saito, K; Sasaki, S; Tahara, M; Yakumaru, K | 1 |
| Hensley, ML | 1 |
| Takeda, K | 1 |
| Watanabe, H | 1 |
| Okamoto, H; Watanabe, K | 1 |
| Krüger, I; Lindenfelser, R; Scherwitz, P | 1 |
| Gerinière, L; Souquet, PJ | 1 |
| Choy, H; Gandara, D; Mattson, K; Vokes, EE | 1 |
| Friberg, LE; Henningsson, A; Karlsson, MO; Maas, H; Nguyen, L | 1 |
| Naito, K | 1 |
| Hirai, I; Honda, K; Kokawa, Y; Okamura, Y; Oura, S; Sakurai, T; Sasaki, R; Tanino, H; Yoshimasu, T | 1 |
| Bunn, PA; Simon, GR | 1 |
| Albain, KS; Bearden, JD; Burris, H; Chansky, K; Crowley, J; Gandara, DR; Gaspar, LE; Gumerlock, P; Kuebler, JP; Lara, PN; Leigh, BR; Livingston, R | 1 |
| Acquati, M; Ardizzoia, A; Casartelli, C; Fagnani, D; Fusco, O; Giordano, M; Malugani, F; Quattrone, A; Scanni, A; Tagliabue, P; Vergani, C; Visini, M | 1 |
| Cheng, ZW; Zhang, L | 1 |
| Chuman, H | 1 |
| Camlica, H; Demir, C; Tas, F; Topuz, E; Ustuner, Z | 1 |
| Hatae, M; Nakamura, T; Onishi, Y | 1 |
| Herzog, TJ | 1 |
| Battistel, C; Hartung, R; Kübler, HR; Lehmer, A; Paul, R; Treiber, U; van Randenborgh, H; Wagenpfeil, S; Wutzler, S | 1 |
| Sugiyama, T | 1 |
| Asano, K; Egawa, S; Hayashi, N; Manome, Y; Suzuki, H; Tanigawa, N; Yamamoto, T | 1 |
| Epstein, AL; Hu, P; Khawli, LA | 1 |
| Beijnen, JH; Chhatta, AA; Huisman, MT; Schinkel, AH; van Tellingen, O | 1 |
| Brown, J; Burke, TW; Deavers, MT; Gershenson, DM; Munsell, MF; Ramondetta, LM; Shvartsman, HS | 1 |
| Besse, B; Le Chevalier, T; Soria, JC | 1 |
| Mimata, H; Nomura, T; Nomura, Y; Yamasaki, M | 1 |
| Bunn, P; Kelly, K; Magree, L; Rabinovitch, R; Sunpaweravong, P | 1 |
| Kawauchi, A; Miki, T; Mizutani, Y; Nakamura, T; Nomoto, T | 1 |
| Iwashige, A; Kagami, S; Tsukada, J; Uramoto, H | 1 |
| Fournel, P | 1 |
| Katakami, N | 1 |
| Chatelut, E; Henningsson, A; Karlsson, MO; Kloft, C; Wallin, J | 1 |
| Admirand, JH; Bueso-Ramos, CE; Ford, RJ; Jiang, L; Moran, C | 1 |
| Ono, A; Yamamoto, N | 1 |
| Yoneda, S | 1 |
| Calvo, A; de las Rivas, J; Gonzalez-Moreno, O; Nguewa, P; Segura, V; Serrano, D | 1 |
| Abbruzzese, A; Agostinelli, E; Budillon, A; Caraglia, M; Giuberti, G; Lombardi, A; Marra, M; Meo, G; Tempera, G | 1 |
| Bookman, MA | 1 |
| Fujiwara, Y; Kunitoh, H; Nokihara, H; Ohe, Y; Sekine, I; Tamura, T; Tsuta, K; Yamada, K; Yamamoto, N | 1 |
| Slovin, SF | 1 |
| Albain, KS; Chansky, K; Crowley, JJ; Gandara, DR; Gaspar, LE; Jett, J; Kelly, K; Lau, DH; Ung, YC | 1 |
| Alexandrova, EN; Istomin, YP; Petrovich, SV; Sergeyeva, OP; Zhavrid, EA | 1 |
| Fu, JM; Li, H; Xie, JS; Zhou, J | 1 |
| Druker, BJ; Elsea, CR; Roberts, DA; Wood, LJ | 1 |
| Ahn, JS; Ahn, MJ; Ahn, YC; Han, J; Hwang, IG; Kim, J; Lee, S; Park, BB; Park, K; Shim, YM | 1 |
| Choong, NW; Dancey, JE; Grushko, T; Haraf, DJ; Hoffman, PC; Kozloff, M; Lester, E; Lin, S; Mauer, AM; Olopade, OI; Salgia, R; Szeto, L; Vokes, EE | 1 |
| Ross, HJ; Seung, SK | 1 |
| Anderson, T; Ansari, R; Arseneau, J; Breen, T; Bruetman, D; Chowhan, N; Einhorn, L; Fisher, W; Govindan, R; Hanna, N; Johnson, C; Mantravadi, P; McGarry, R; Melnyk, A; Nattam, S; Neubauer, M; Reynolds, C; Richards, D; White, A; Yiannoutsos, C | 1 |
| Bossi, A; Di Palma, M; Escudier, B; Fizazi, K; Gross-Goupil, M; Loriot, Y; Massard, C | 1 |
| Hou, LA; Hou, MF; Lin, CY; Ma, H; Tsai, LY; Tsai, SM; Wu, SH | 1 |
| Friberg, LE; Hansson, EK; Karlsson, MO; Lindman, H; Sandström, M; Wallin, JE | 1 |
| Arima, N; Hayashi, M; Nishimura, R; Okumura, Y; Osako, T | 1 |
| Alici, S; Benekli, M; Buyukberber, S; Camci, C; Coskun, U; Dane, F; Gumus, M; Kalender, ME; Kaya, AO; Ozturk, B; Sevinc, A; Uncu, D; Yaman, E; Yildiz, R | 1 |
| Bazan, F; Dixit, VM; Dornan, D; Eastham-Anderson, J; Ferrando, R; French, DM; Huang, DC; Huang, X; Lill, JR; Liu, J; Maecker, H; O'Rourke, K; Schwickart, M; Yue, P | 1 |
| Bazin, IS; Fedyanin, MY; Garin, AM; Kanagavel, D; Narimanov, MN; Pokataev, IA; Tjulandin, SA; Tryakin, AA; Yakovleva, ES | 1 |
| Barriger, RB; Fakiris, AJ; Hanna, N; Mantravadi, P; McGarry, RC; Yu, M | 1 |
| Feigenberg, S; Huang, CH; Jotte, RM; Langer, CJ; Monberg, MJ; Movsas, B; Obasaju, CK; Ross, HJ; Wang, L; Xu, F | 1 |
| Akbulut, H; Demirkazık, A; Icli, F; Onur, H; Senler, FÇ; Yalcin, B | 1 |
| Agelaki, S; Androulakis, N; Bozionelou, V; Georgoulias, V; Hatzidaki, D; Kalbakis, K; Kalykaki, A; Kotsakis, A; Saridaki, Z; Vamvakas, L; Vardakis, N | 1 |
| Fanti, PA; Misciali, C; Miteva, M; Romanelli, P; Tosti, A; Vincenzi, C | 1 |
| Brown, JB; Kadoyama, K; Kuwahara, A; Okuno, Y; Sakaeda, T; Yamamori, M | 1 |
| Agarwala, A; Ansari, R; Breen, T; Bruetman, D; Einhorn, L; Fisher, W; Govindan, R; Hanna, N; Jalal, SI; Johnson, CS; Melnyk, A; Neubauer, M; Richards, D; Riggs, HD; Yu, M | 1 |
| Anish, C; Bagchi, T; Jinturkar, KA; Kumar, MK; Misra, AR; Panda, AK | 1 |
| Baudrin, L; Belmont, L; Cadranel, J; Danel, S; Epaud, C; Gounant, V; Lavolé, A; Milleron, B; Rosencher, L; Ruppert, AM | 1 |
| Bronich, TK; Han, Y; He, Z; Jordan, R; Kabanov, AV; Luxenhofer, R; Schulz, A | 1 |
| Furuya, K; Goto, T; Kato, M; Kita, T; Kudoh, K; Miyamoto, M; Sasaki, N; Takano, M; Watanabe, A; Yoshikawa, T | 1 |
| Hao, J; Liu, GY; Wang, DH; Xu, YF; Yu, J; Yuan, BB | 1 |
| Hayakawa, Y; Hirano, K; Iguchi, K; Ishii, K; Matsumoto, K; Sugimura, Y; Usui, S | 1 |
| Fujii, Y; Kihara, K; Komai, Y; Noguchi, N; Waseda, Y; Yano, A | 1 |
| Ilson, DH | 1 |
| Abonyi-Tóth, Z; Katona, L; Kovács, G; Moldvay, J; Rokszin, G | 1 |
| Chang, C; Chen, Y; Ding, XF; Huang, CK; Lee, SO; Li, G; Lin, SJ; Luo, J; Shan, YX; Wang, R; Yang, DR; Zhu, J | 1 |
| Bompas, E; Clarisse, B; Cojocarasu, O; Delva, R; Eymard, JC; Guillot, A; Houede, N; Joly, F; Leconte, A; Lheureux, S; Linassier, C; Mourey, L; Oudard, S; Ravaud, A; Ringensen, F; Sevin, E; Tubiana-Mathieu, N; Valenza, B; Vedrine, L | 1 |
| Bastide, C; Beuzeboc, P; Brenot-Rossi, I; Bruyère, F; Guy, L; Karsenty, G; Mongiat-Artus, P | 1 |
| Elsing, C; Hannig, CV; Herrmann, C; Herrmann, T; Jäger, D; Stremmel, W | 1 |
| Cao, Y; Chen, X; Chen, Y; Li, X; Ni, D; Shen, K; Tang, J; Wei, Z; Wu, K; Xie, X; Ye, G; Zhang, C; Zheng, H | 1 |
| Furuse, H; Ishii, Y; Kai, F; Nagata, M; Otsuka, A; Ozono, S; Sugiyama, T; Suzuki, T; Takayama, T; Yajima, T | 1 |
| Arce-Lara, C; Kelley, MJ; Santana-Davila, R; Szabo, A; Whittle, J; Williams, CD | 1 |
| Bacakoglu, F; Cok, G; Erdinc, M; Goker, E; Goksel, O; Goksel, T; Karakus, H; Uslu, R | 1 |
| Adachi, S; Endo, I; Ichikawa, Y; Ishikawa, T; Kida, K; Narui, K; Sasaki, T; Satake, T; Shimada, K; Shimizu, D; Sugae, S; Tanabe, M; Yamada, A | 1 |
| Chakravarty, A; Mettetal, JT; Palani, S; Patel, M; Shyu, WC; Yang, J | 1 |
| Wang, W; Wang, Z; Xiao, X | 1 |
| Fitzgerald, TJ; Gandara, DR; Gaspar, LE; Kelly, K; Mack, PC; Moon, J; Pandya, KJ; Raben, D; Thomas, CR; Wozniak, AJ | 1 |
| Abesada-Terk, G; Alemany, C; Brown, RH; Cartwright, TH; Faig, D; Fulp, WJ; Jacobsen, PB; Kim, GP; Lee, JH; Levine, RM; Malafa, M; Markham, MJ; Schreiber, F; Sharp, PV; Tanvetyanon, T | 1 |
| Al-Massarani, G; Alammar, M; Banat, I; Najjar, F | 1 |
| Gomez, D; Komaki, R; Lee, MS; Levy, LB; Liao, Z; Lu, C; Tang, C; Zhuang, Y | 1 |
| Blomen, V; Brummelkamp, TR; Hoogstraat, M; Janssen, L; Lips, EH; Neefjes, J; Pang, B; Qiao, X; van der Zanden, SY; Wessels, L; Wijdeven, RH | 1 |
| Aliustaoglu, M; Aydin, D; Ercelep, O; Gemici, C; Gumus, M; Isik, D; Korkmaz, T; Mayadagli, A; Mert, AG; Odabas, H; Ozcelik, M; Ozdemir, P; Seker, M; Surmeli, H; Yuksel, S | 1 |
| Aydiner, A; Ciftci, R; Demir, A; Eralp, Y; Firat, P; Guveli, ME; Oral, EN; Ozkan, B; Ozkaya, K; Saglam, EK; Saip, P; Sen, F; Tambas, M; Toker, A | 1 |
| Belaaloui, G; Jiang, ZZ; Khaled, M; Zhang, LY; Zhu, X | 1 |
| Amini, M; Belderbos, JSA; Biesma, B; Bootsma, GP; Brouns, -JWM; Bussink, J; De Ruysscher, DKM; Dingemans, AC; Hendriks, LEL; Oei, SB; Stigt, JA; Uyterlinde, W; Van den Heuvel, MM; Wijsman, R | 1 |
| Damhuis, RA; den Bakker, MA; Derks, JL; Dingemans, AC; Groen, HJ; Smit, EF; Speel, EM; Thunnissen, E; van den Broek, EC; van Suylen, RJ | 1 |
| Akiba, J; Azuma, K; Hoshino, T; Ishii, H; Masuda, K; Matsuo, N; Naito, Y; Sakazaki, Y; Tokito, T; Tsuneyoshi, S; Yamada, K; Zaizen, Y | 1 |
| Ajona, D; Calvo, A; Cirauqui, C; de Aberasturi, AL; de Andrea, C; Exposito, F; Guruceaga, E; Montuenga, LM; Pio, R; Redin, E; Redrado, M; Vicent, S; Villalba, M | 1 |
| Cai, S; Cai, Y; Cheng, X; Dai, Z; Jia, H; Jiang, R; Luan, Y; Pu, H; Shi, T; Tang, J; Tu, D; Tu, R; Wang, H; Yang, H; Zang, R; Zhang, Y | 1 |
| Cramer-van der Welle, CM; Groen, HJM; Schramel, FMNH; van de Garde, EMW; van Leeuwen, AS | 1 |
| Akdeniz, N; Alan, Ö; Bilen, E; Ebinç, S; Ercelep, Ö; Işıkdoğan, A; Kaplan, MA; Karhan, O; Küçüköner, M; Laçin, Ş; Sezgin, Y; Teke, F; Urakçı, Z; Yumuk, PF | 1 |
| Ayadi, M; Bahri, O; Berjeb, KK; Braham, M; Chakroun, N; Chtourou, S; Debbabi, L; Fadhlaoui, A; Hamdoun, M; Hannachi, H; Kacem, K; Zemni, Z; Zhioua, F | 1 |
| Bellet, MM; Castelli, M; Costantini, C; Della-Fazia, MA; Gargaro, M; Pieroni, S; Piobbico, D; Romani, L; Sassone-Corsi, P; Servillo, G; Stincardini, C | 1 |
| Chao, OS; Goodman, OB | 1 |
| Chatterjee, B; Ganti, S; Pandya, M | 1 |
| Min, S; Zheng, Q; Zhou, Y | 1 |
| Bonnabry, P; Fleury-Souverain, S; Guillarme, D; Maurin, J; Rudaz, S | 1 |
| Li, Y; Xu, F; Zhou, H | 1 |
29 review(s) available for docetaxel anhydrous and etoposide
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
["State-of-the-art" chemotherapy for small-cell lung cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Small Cell; Cisplatin; Clinical Trials as Topic; Cyclophosphamide; Deoxycytidine; Docetaxel; Doxorubicin; Drug Administration Schedule; Etoposide; Gemcitabine; Humans; Irinotecan; Lung Neoplasms; Paclitaxel; Taxoids; Topotecan; Vincristine | 1997 |
Chemotherapy for gastric carcinoma: new and old options.
Topics: Administration, Oral; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Camptothecin; Capecitabine; Deoxycytidine; Docetaxel; Drug Combinations; Enzyme Inhibitors; Etoposide; Fluorouracil; Humans; Infusions, Intravenous; Irinotecan; Oxonic Acid; Paclitaxel; Pyridines; Randomized Controlled Trials as Topic; Stomach Neoplasms; Taxoids; Tegafur; Uracil | 1998 |
[Irinotecan-containing combinations in solid tumors, except colonic carcinomas].
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Cisplatin; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Diarrhea; Docetaxel; Enzyme Inhibitors; Etoposide; Female; Genital Neoplasms, Female; Humans; Irinotecan; Lung Neoplasms; Lymphoma, Non-Hodgkin; Male; Neoplasm Proteins; Neoplasms; Neutropenia; Paclitaxel; Stomach Neoplasms; Taxoids; Topoisomerase I Inhibitors; Treatment Outcome | 1998 |
Chemoradiation in locally advanced non-small cell lung cancer.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical Trials, Phase III as Topic; Combined Modality Therapy; Deoxycytidine; Docetaxel; Drug Administration Schedule; Etoposide; Forecasting; Gemcitabine; Humans; Irinotecan; Lung Neoplasms; Multicenter Studies as Topic; Paclitaxel; Radiotherapy, Adjuvant; Randomized Controlled Trials as Topic; Survival Rate; Taxoids; Treatment Outcome; Vinblastine; Vinorelbine | 2001 |
Lung cancer: therapeutic options for stage IV and recurrent NSCLC.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Combined Modality Therapy; Deoxycytidine; Docetaxel; Etoposide; Gemcitabine; Humans; Irinotecan; Lung Neoplasms; Multicenter Studies as Topic; Neoplasm Recurrence, Local; Paclitaxel; Prognosis; Randomized Controlled Trials as Topic; Risk Factors; Survival Rate; Taxoids; Teniposide; Treatment Outcome; Vinblastine; Vinorelbine | 2001 |
Body surface area as a determinant of pharmacokinetics and drug dosing.
Topics: Adult; Animals; Anthropometry; Antineoplastic Agents; Area Under Curve; Body Surface Area; Carboplatin; Cardiac Output; Child; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Etoposide; Humans; Kidney; Liver; Medical Oncology; Neoplasms; Paclitaxel; Taxoids | 2001 |
Paclitaxel and docetaxel in prostate cancer.
Topics: Adenocarcinoma; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carboplatin; Chemotherapy, Adjuvant; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Dexamethasone; Docetaxel; Drug Administration Schedule; Drug Resistance, Neoplasm; Enzyme Inhibitors; Estramustine; Etoposide; Genes, bcl-2; Humans; Hydrocortisone; Male; Microtubules; Mitosis; Mitoxantrone; Multicenter Studies as Topic; Neoplasm Proteins; Oligodeoxyribonucleotides, Antisense; Paclitaxel; Palliative Care; Prostatic Neoplasms; Protein Processing, Post-Translational; Proto-Oncogene Proteins c-bcl-2; Signal Transduction; Survival Analysis; Taxoids; Treatment Outcome; Tubulin | 2001 |
Topoisomerase I inhibitors combination chemotherapy in non-small cell lung cancer.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical Trials as Topic; Combined Modality Therapy; Deoxycytidine; Docetaxel; Doxorubicin; Enzyme Inhibitors; Etoposide; Gemcitabine; Humans; Ifosfamide; Irinotecan; Lung Neoplasms; Paclitaxel; Taxoids; Topoisomerase I Inhibitors; Topotecan; Vinblastine; Vinorelbine | 2001 |
Epithelial ovarian cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bridged-Ring Compounds; Combined Modality Therapy; Deoxycytidine; Docetaxel; Doxorubicin; Etoposide; Female; Gemcitabine; Humans; Ifosfamide; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel; Platinum Compounds; Practice Guidelines as Topic; Tamoxifen; Taxoids; Topotecan; Vinblastine; Vinorelbine | 2002 |
[Gemcitabine].
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Docetaxel; Etoposide; Gemcitabine; Humans; Lung Neoplasms; Paclitaxel; Randomized Controlled Trials as Topic; Taxoids; Vinblastine; Vinorelbine | 2002 |
[Carboplatin].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Docetaxel; Etoposide; Gemcitabine; Humans; Lung Neoplasms; Paclitaxel; Randomized Controlled Trials as Topic; Taxoids; Treatment Outcome | 2002 |
[Chemotherapy for elderly patients with lung cancer].
Topics: Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Cisplatin; Clinical Trials as Topic; Deoxycytidine; Docetaxel; Doxorubicin; Etoposide; Gemcitabine; Humans; Lung Neoplasms; Paclitaxel; Taxoids; Vinblastine; Vincristine; Vinorelbine | 2002 |
[Combinations of platinum salts and gemcitabine in the treatment of non-small-cell lung cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical Trials, Phase III as Topic; Combined Modality Therapy; Deoxycytidine; Docetaxel; Etoposide; Gastrointestinal Diseases; Gemcitabine; Hematologic Diseases; Humans; Lung Neoplasms; Neoadjuvant Therapy; Paclitaxel; Pneumonectomy; Randomized Controlled Trials as Topic; Remission Induction; Reproducibility of Results; Taxoids; Treatment Outcome; Vinblastine; Vinorelbine | 2002 |
Adjuvant and neoadjuvant treatments for NSCLC.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Cisplatin; Docetaxel; Dose Fractionation, Radiation; Etoposide; Humans; Lung Neoplasms; Neoadjuvant Therapy; Paclitaxel; Radiotherapy, Adjuvant; Survival; Taxoids | 2002 |
[Chemotherapy for prostate cancers].
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Drug Administration Schedule; Estramustine; Etoposide; Humans; Male; Paclitaxel; Prostatic Neoplasms; Taxoids; Vinblastine | 2002 |
Taxanes in the treatment of advanced (stage III and IV) non-small cell lung cancer (NSCLC): recent developments.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Combined Modality Therapy; Deoxycytidine; Docetaxel; Etoposide; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Microtubules; Multicenter Studies as Topic; Neoadjuvant Therapy; Organoplatinum Compounds; Paclitaxel; Palliative Care; Podophyllotoxin; Randomized Controlled Trials as Topic; Salvage Therapy; Survival Analysis; Taxoids; Teniposide; Treatment Outcome; Vinblastine; Vinorelbine | 2003 |
[Chemotherapy of the elderly patients with advanced non-small cell lung cancer].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Docetaxel; Drug Administration Schedule; Etoposide; Gemcitabine; Humans; Lung Neoplasms; Neoplasm Staging; Retrospective Studies; Signal Transduction; Taxoids | 2004 |
[Current strategy of chemotherapy for reflactory bone and soft tissue sarcomas].
Topics: Antineoplastic Combined Chemotherapy Protocols; Benzamides; Bone Neoplasms; Carboplatin; Cisplatin; Clinical Trials, Phase II as Topic; Docetaxel; Drug Administration Schedule; Etoposide; Humans; Ifosfamide; Imatinib Mesylate; Lung Neoplasms; Piperazines; Prognosis; Pyrimidines; Randomized Controlled Trials as Topic; Sarcoma; Soft Tissue Neoplasms; Survival Rate; Taxoids | 2004 |
[Treatment of platinum-resistant ovarian cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Clinical Trials as Topic; DNA Damage; Docetaxel; Drug Resistance, Neoplasm; Etoposide; Female; Gynecologic Surgical Procedures; Humans; Irinotecan; Neoplasm Recurrence, Local; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Taxoids; Treatment Outcome | 2004 |
Recurrent ovarian cancer: how important is it to treat to disease progression?
Topics: Altretamine; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Deoxycytidine; Disease Progression; Docetaxel; Doxorubicin; Etoposide; Female; Gemcitabine; Humans; Ovarian Neoplasms; Paclitaxel; Recurrence; Risk; Taxoids; Time Factors; Topotecan | 2004 |
[Second-line chemotherapy for recurrent ovarian cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Cisplatin; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Cyclophosphamide; Docetaxel; Doxorubicin; Drug Administration Schedule; Drug Resistance, Neoplasm; Etoposide; Female; Humans; Irinotecan; Ovarian Neoplasms; Paclitaxel; Platinum; Taxoids | 2005 |
[Progress in therapy for testicular tumors].
Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Camptothecin; Cisplatin; Combined Modality Therapy; Deoxycytidine; Docetaxel; Drug Administration Schedule; Etoposide; Gemcitabine; Humans; Irinotecan; Lymph Node Excision; Male; Paclitaxel; Taxoids; Testicular Neoplasms | 2006 |
[Chemotherapy for lung cancer patients].
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Chemotherapy, Adjuvant; Cisplatin; Docetaxel; Erlotinib Hydrochloride; Etoposide; Evidence-Based Medicine; Gefitinib; Humans; Irinotecan; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines; Randomized Controlled Trials as Topic; Taxoids | 2006 |
[Lung cancer].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Cisplatin; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Docetaxel; Drug Administration Schedule; Etoposide; Glutamates; Guanine; Humans; Irinotecan; Lung Neoplasms; Pemetrexed; Taxoids | 2007 |
Anticancer drugs and hyperthermia enhance cytotoxicity induced by polyamine enzymatic oxidation products.
Topics: Adenosylmethionine Decarboxylase; Amine Oxidase (Copper-Containing); Animals; Antineoplastic Agents; Caspases; Cattle; Cell Proliferation; Docetaxel; Drug Synergism; Etoposide; Eukaryotic Translation Initiation Factor 5A; Humans; Hyperthermia, Induced; Interferon-alpha; Lysine; Ornithine Decarboxylase; Oxidation-Reduction; Peptide Initiation Factors; Polyamines; RNA-Binding Proteins; Taxoids | 2007 |
[The non-hormonal treatment of metastatic prostate cancer].
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bone Density Conservation Agents; Cisplatin; Denosumab; Docetaxel; Etoposide; Humans; Male; Mitoxantrone; Organometallic Compounds; Organophosphorus Compounds; Osteoporosis; Prostatic Neoplasms; Radiation Protection; Radioisotopes; Radium; RANK Ligand; Strontium; Strontium Radioisotopes; Taxoids | 2013 |
The role of chemotherapy for metastatic, relapsed and refractory osteosarcoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Cyclophosphamide; Deoxycytidine; Docetaxel; Etoposide; Gemcitabine; Humans; Ifosfamide; Methotrexate; Neoplasm Recurrence, Local; Osteosarcoma; Taxoids | 2014 |
A network meta-analysis for efficacies and toxicities of different concurrent chemoradiotherapy regimens in the treatment of locally advanced non-small cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Chemoradiotherapy; Cisplatin; Docetaxel; Etoposide; Humans; Irinotecan; Lung Neoplasms; Network Meta-Analysis; Paclitaxel; Pemetrexed; Vinorelbine | 2022 |
16 trial(s) available for docetaxel anhydrous and etoposide
| Article | Year |
|---|---|
Prevention of chemotherapy-induced alopecia using an effective scalp cooling system.
Topics: Adult; Aged; Alopecia; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cryotherapy; Docetaxel; Etoposide; Female; Humans; Male; Middle Aged; Neoplasms; Paclitaxel; Scalp; Taxoids | 2000 |
Consolidation docetaxel after concurrent chemoradiotherapy in stage IIIB non-small-cell lung cancer: phase II Southwest Oncology Group Study S9504.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Combined Modality Therapy; Disease-Free Survival; Docetaxel; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Survival Analysis; Taxoids; Treatment Outcome; United States | 2003 |
Second line therapy with weekly low-dose docetaxel for pretreated non-small-cell lung carcinoma patients: a multicenter Italian phase II study.
Topics: Adult; Aged; Alopecia; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Asthenia; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Resistance, Neoplasm; Esophagitis; Etoposide; Female; Follow-Up Studies; Gemcitabine; Hematologic Diseases; Humans; Lung Neoplasms; Male; Middle Aged; Neurotoxicity Syndromes; Premedication; Remission Induction; Stomatitis; Survival Rate; Taxoids; Treatment Outcome; Vinblastine; Vinorelbine | 2004 |
Second-Line docetaxel and gemcitabine combination chemotherapy in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy: a phase II trial.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Chi-Square Distribution; Cisplatin; Deoxycytidine; Disease-Free Survival; Docetaxel; Etoposide; Female; Follow-Up Studies; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Taxoids; Time Factors; Vinblastine; Vinorelbine | 2004 |
A phase I/II study of docetaxel, etoposide, and carboplatin before concurrent chemoradiotherapy with cisplatin and etoposide in limited-stage small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Small Cell; Cisplatin; Combined Modality Therapy; Docetaxel; Etoposide; Female; Humans; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neutropenia; Taxoids; Treatment Outcome | 2006 |
Phase III trial of maintenance gefitinib or placebo after concurrent chemoradiotherapy and docetaxel consolidation in inoperable stage III non-small-cell lung cancer: SWOG S0023.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Combined Modality Therapy; Docetaxel; Etoposide; Female; Follow-Up Studies; Gefitinib; Humans; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Prognosis; Quinazolines; Remission Induction; Survival Rate; Taxoids | 2008 |
Phase I trial of erlotinib-based multimodality therapy for inoperable stage III non-small cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Combined Modality Therapy; Docetaxel; ErbB Receptors; Erlotinib Hydrochloride; Etoposide; Female; Gene Amplification; Humans; In Situ Hybridization, Fluorescence; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Prognosis; Protein Kinase Inhibitors; Quinazolines; Remission Induction; Survival Rate; Taxoids | 2008 |
Phase II trial of combined modality therapy with concurrent topotecan plus radiotherapy followed by consolidation chemotherapy for unresectable stage III and selected stage IV non-small-lung cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Docetaxel; Etoposide; Female; Follow-Up Studies; Hematologic Diseases; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Pilot Projects; Taxoids; Topotecan | 2009 |
Phase III study of cisplatin, etoposide, and concurrent chest radiation with or without consolidation docetaxel in patients with inoperable stage III non-small-cell lung cancer: the Hoosier Oncology Group and U.S. Oncology.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Cisplatin; Docetaxel; Etoposide; Female; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Radiotherapy, Adjuvant; Taxoids; Time Factors; Treatment Outcome | 2008 |
A prognostic model in patients treated for metastatic gastric cancer with second-line chemotherapy.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Signet Ring Cell; Cisplatin; Docetaxel; Etoposide; Female; Fluorouracil; Follow-Up Studies; Humans; Liver Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Mitomycin; Neoplasm Staging; Ovarian Neoplasms; Peritoneal Neoplasms; Prognosis; Retrospective Studies; Stomach Neoplasms; Survival Rate; Taxoids | 2010 |
Dose-volume analysis of radiation pneumonitis in non-small-cell lung cancer patients treated with concurrent cisplatinum and etoposide with or without consolidation docetaxel.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Combined Modality Therapy; Docetaxel; Etoposide; Humans; Lung; Lung Neoplasms; Middle Aged; Radiation Pneumonitis; Radiotherapy Dosage; Retrospective Studies; Taxoids; Tumor Burden | 2010 |
Randomized phase II trial of cisplatin, etoposide, and radiation followed by gemcitabine alone or by combined gemcitabine and docetaxel in stage III A/B unresectable non-small cell lung cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Combined Modality Therapy; Deoxycytidine; Docetaxel; Etoposide; Feasibility Studies; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Radiotherapy Dosage; Survival Rate; Taxoids; Treatment Outcome | 2010 |
Updated survival and outcomes for older adults with inoperable stage III non-small-cell lung cancer treated with cisplatin, etoposide, and concurrent chest radiation with or without consolidation docetaxel: analysis of a phase III trial from the Hoosier O
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Chemoradiotherapy; Cisplatin; Consolidation Chemotherapy; Disease-Free Survival; Docetaxel; Early Termination of Clinical Trials; Etoposide; Female; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Taxoids; Treatment Outcome | 2012 |
Clinical benefits of non-taxane chemotherapies in unselected patients with symptomatic metastatic castration-resistant prostate cancer after docetaxel: the GETUG-P02 study.
Topics: Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Etoposide; Humans; Male; Middle Aged; Mitoxantrone; Neoplasm Metastasis; Palliative Care; Prednisone; Prostatic Neoplasms, Castration-Resistant; Taxoids; Vinblastine; Vinorelbine | 2015 |
Superior outcome after neoadjuvant chemotherapy with docetaxel, anthracycline, and cyclophosphamide versus docetaxel plus cyclophosphamide: results from the NATT trial in triple negative or HER2 positive breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Docetaxel; Etoposide; Female; Humans; Lymphatic Metastasis; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Receptor, ErbB-2; Taxoids; Treatment Outcome; Triple Negative Breast Neoplasms | 2013 |
Survival benefits of dose-dense early postoperative intraperitoneal chemotherapy in front-line therapy for advanced ovarian cancer: a randomised controlled study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Ovarian Epithelial; Chemotherapy, Adjuvant; Cisplatin; Cytoreduction Surgical Procedures; Docetaxel; Etoposide; Female; Humans; Infusions, Intravenous; Infusions, Parenteral; Middle Aged; Neoplasm Staging; Ovarian Neoplasms; Ovariectomy; Paclitaxel; Progression-Free Survival; Proportional Hazards Models; Survival Rate; Treatment Outcome; Young Adult | 2019 |
83 other study(ies) available for docetaxel anhydrous and etoposide
| Article | Year |
|---|---|
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Some Anticancer Agents Act on Human Serum Paraoxonase-1 to Reduce Its Activity.
Topics: Antineoplastic Agents; Aryldialkylphosphatase; Electrophoresis, Polyacrylamide Gel; Humans | 2016 |
Four new antitumor metabolites isolated from a mutant 3-f-31 strain derived from Penicillium purpurogenum G59.
Topics: Animals; Antineoplastic Agents; Apoptosis; Biological Products; Cell Line, Tumor; HCT116 Cells; Humans; Mice; Models, Molecular; Mutation; Neoplasms; Penicillium | 2018 |
Synthesis and anti-HSV activity of tricyclic penciclovir and hydroxybutylguanine derivatives.
Topics: Acyclovir; Antiviral Agents; Guanine; Herpes Genitalis; Herpes Simplex; Herpesvirus 1, Human; Herpesvirus 2, Human; Humans; Models, Molecular | 2019 |
Synthesis and Antitumor Activity of C-7-Alkynylated and Arylated Pyrrolotriazine C-Ribonucleosides.
Topics: | 2020 |
Comparative in vitro cytotoxicity of taxol and Taxotere against cisplatin-sensitive and -resistant human ovarian carcinoma cell lines.
Topics: Antineoplastic Agents, Phytogenic; Cell Death; Cisplatin; Docetaxel; Doxorubicin; Drug Resistance; Drug Screening Assays, Antitumor; Etoposide; Female; Humans; Ovarian Neoplasms; Paclitaxel; Rhodamines; Taxoids; Tumor Cells, Cultured | 1992 |
[Recent advances in ovarian cancer chemotherapy].
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carboplatin; Cisplatin; Cyclophosphamide; Docetaxel; Doxorubicin; Etoposide; Female; Humans; Infusions, Parenteral; Neoplasms, Germ Cell and Embryonal; Ovarian Neoplasms; Paclitaxel; Taxoids | 1992 |
Plasma concentrations of polysorbate 80 measured in patients following administration of docetaxel or etoposide.
Topics: Aged; Antineoplastic Agents, Phytogenic; Docetaxel; Etoposide; Female; Humans; Male; Middle Aged; Neoplasms; Paclitaxel; Polysorbates; Surface-Active Agents; Taxoids | 1997 |
In vitro effect of amifostine on haematopoietic progenitors exposed to carboplatin and non-alkylating antineoplastic drugs: haematoprotection acts as a drug-specific progenitor rescue.
Topics: Amifostine; Antigens, CD34; Antineoplastic Agents; Apoptosis; ATP Binding Cassette Transporter, Subfamily B, Member 1; Carboplatin; Cell Cycle; Cell Division; Cells, Cultured; Docetaxel; Doxorubicin; Etoposide; Hematopoietic Stem Cells; Humans; Leukocytes, Mononuclear; Paclitaxel; Taxoids; Time Factors | 1998 |
Activation and the interaction of proapoptotic genes in modulating sensitivity to anticancer drugs in gastric cancer cells.
Topics: Antineoplastic Agents; Apoptosis; bcl-2-Associated X Protein; bcl-X Protein; Cisplatin; DNA Fragmentation; Docetaxel; Doxorubicin; Drug Screening Assays, Antitumor; Etoposide; Humans; Inhibitory Concentration 50; Paclitaxel; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-bcl-2; RNA, Messenger; Signal Transduction; Stomach Neoplasms; Taxoids; Transfection; Tumor Cells, Cultured; Tumor Suppressor Protein p53; Up-Regulation | 1999 |
Resistance to taxanes is induced by c-erbB-2 overexpression in human MCF-10A mammary epithelial cells and is blocked by combined treatment with an antisense oligonucleotide targeting type I protein kinase A.
Topics: Antineoplastic Agents; Breast; Breast Neoplasms; Carboplatin; Cell Division; Cell Line; Cell Line, Transformed; Cell Survival; Cisplatin; Cyclic AMP-Dependent Protein Kinase Type II; Cyclic AMP-Dependent Protein Kinases; Docetaxel; Doxorubicin; Epithelial Cells; Etoposide; Female; Genes, erbB-2; Humans; Oligodeoxyribonucleotides, Antisense; Paclitaxel; Receptor, ErbB-2; Taxoids; Topoisomerase I Inhibitors; Topoisomerase II Inhibitors; Topotecan; Tumor Cells, Cultured | 2000 |
Rapid in vivo monitoring of chemotherapeutic response using weighted sodium magnetic resonance imaging.
Topics: Animals; Annexin A5; Antineoplastic Agents, Phytogenic; Apoptosis; Cell Nucleus; Docetaxel; Etoposide; Flow Cytometry; Fluorescent Antibody Technique; Fluorescent Dyes; Humans; Magnetic Resonance Imaging; Male; Mice; Neoplasm Transplantation; Paclitaxel; Phantoms, Imaging; Prostatic Neoplasms; Sodium; Sodium Chloride; Taxoids; Time Factors; Treatment Outcome; Tumor Cells, Cultured | 2000 |
[Outpatient chemotherapy for advanced lung cancer].
Topics: Adenocarcinoma; Adult; Aged; Ambulatory Care; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Small Cell; Carcinoma, Squamous Cell; Docetaxel; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Survival Rate; Taxoids | 2001 |
[An autopsy case of pulmonary and central nervous system metastatic osteosarcoma treated with thirty-six courses of chemotherapy over four years].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Brain Neoplasms; Carboplatin; Cisplatin; Dacarbazine; Deoxycytidine; Docetaxel; Drug Administration Schedule; Etoposide; Gemcitabine; Humans; Ifosfamide; Lung Neoplasms; Male; Methotrexate; Osteosarcoma; Paclitaxel; Spinal Cord Neoplasms; Survivors; Taxoids; Vincristine; Vindesine | 2002 |
[Localization of primary small cell carcinoma with liver metastasis: a rare combination of colonic adenocarcinoma and undifferentiated small cell carcinoma].
Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Small Cell; Colectomy; Colon; Colonic Neoplasms; Docetaxel; Doxorubicin; Etoposide; Female; Humans; Immunohistochemistry; Liver; Liver Neoplasms; Neoplasms, Multiple Primary; Neoplasms, Unknown Primary; Paclitaxel; Taxoids; Time Factors; Vincristine | 2002 |
Model of chemotherapy-induced myelosuppression with parameter consistency across drugs.
Topics: Antineoplastic Agents; Bone Marrow; Camptothecin; Deoxycytidine; Docetaxel; Etoposide; Humans; Irinotecan; Leukocytes; Models, Biological; Neutrophils; Paclitaxel; Taxoids; Vinblastine | 2002 |
[Histoculture drug response assay (HDRA) guided induction concurrent chemoradiotherapy for mediastinal node-positive non-small cell lung cancer].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Combined Modality Therapy; Docetaxel; Drug Screening Assays, Antitumor; Etoposide; Female; Humans; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Paclitaxel; Pneumonectomy; Taxoids; Tumor Cells, Cultured | 2003 |
In vitro cytotoxic effects of imatinib in combination with anticancer drugs in human prostate cancer cell lines.
Topics: Antineoplastic Agents; Antineoplastic Agents, Hormonal; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Cell Line, Tumor; Cyclophosphamide; Docetaxel; Drug Synergism; Estramustine; Etoposide; Humans; Imatinib Mesylate; Immunohistochemistry; In Vitro Techniques; Male; Piperazines; Prostatic Neoplasms; Proto-Oncogene Proteins c-kit; Pyrimidines; Receptors, Platelet-Derived Growth Factor; Taxoids | 2005 |
Adenoviral infection of survivin antisense sensitizes prostate cancer cells to etoposide in vivo.
Topics: Adenoviridae; Animals; Antisense Elements (Genetics); Apoptosis; Cell Line, Tumor; Cell Proliferation; Docetaxel; Etoposide; Humans; Inhibitor of Apoptosis Proteins; Male; Mice; Mice, Inbred BALB C; Microtubule-Associated Proteins; Neoplasm Proteins; Neoplasm Transplantation; Prostatic Neoplasms; Survivin; Taxoids; Transplantation, Heterologous | 2005 |
NHS76/PEP2, a fully human vasopermeability-enhancing agent to increase the uptake and efficacy of cancer chemotherapy.
Topics: Animals; Antibodies, Monoclonal; Antineoplastic Agents; Capillary Permeability; Cell Line, Tumor; Docetaxel; Dose-Response Relationship, Drug; Doxorubicin; Etoposide; Female; Fluorouracil; Humans; Injections, Intravenous; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasms; Paclitaxel; Peptide Fragments; Taxoids; Time Factors; Tissue Distribution; Treatment Outcome; Vinblastine; Xenograft Model Antitumor Assays | 2005 |
MRP2 (ABCC2) transports taxanes and confers paclitaxel resistance and both processes are stimulated by probenecid.
Topics: Animals; Antineoplastic Agents, Phytogenic; Biological Transport; Cell Line; Docetaxel; Dogs; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Etoposide; Membrane Transport Proteins; Multidrug Resistance-Associated Protein 2; Multidrug Resistance-Associated Proteins; Paclitaxel; Probenecid; Taxoids; Vinblastine | 2005 |
The activity of taxanes compared with bleomycin, etoposide, and cisplatin in the treatment of sex cord-stromal ovarian tumors.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cisplatin; Docetaxel; Etoposide; Female; Humans; Middle Aged; Neoplasm Staging; Organoplatinum Compounds; Ovarian Neoplasms; Paclitaxel; Retrospective Studies; Sex Cord-Gonadal Stromal Tumors; Taxoids | 2005 |
Front-line doublets in advanced non-small cell lung cancer: The golden age for second line chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Disease Progression; Docetaxel; Etoposide; Female; Glutamates; Guanine; Humans; Lung Neoplasms; Male; Paclitaxel; Pemetrexed; Survival Rate; Taxoids | 2005 |
Expression of the inhibitors of apoptosis proteins in cisplatin-resistant prostate cancer cells.
Topics: Apoptosis; Baculoviral IAP Repeat-Containing 3 Protein; Bisbenzimidazole; Cell Line, Tumor; Cell Proliferation; Cisplatin; Docetaxel; Dose-Response Relationship, Drug; Doxorubicin; Drug Resistance; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Etoposide; Fluorouracil; Humans; Immunoblotting; Inhibitor of Apoptosis Proteins; Male; Microtubule-Associated Proteins; Neoplasm Proteins; Neuronal Apoptosis-Inhibitory Protein; Paclitaxel; Phenotype; Prostatic Neoplasms; Survivin; Taxoids; Tetrazolium Salts; Time Factors; Ubiquitin-Protein Ligases; X-Linked Inhibitor of Apoptosis Protein | 2005 |
[From ASCO and WCLC 2005 to clinical practice: "conventional" treatments].
Topics: Administration, Oral; Age Factors; Aged; Angiogenesis Inhibitors; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Chemotherapy, Adjuvant; Cisplatin; Clinical Trials, Phase III as Topic; Deoxycytidine; Docetaxel; Etoposide; Follow-Up Studies; Gemcitabine; Humans; Irinotecan; Lung; Lung Neoplasms; Mediastinoscopy; Meta-Analysis as Topic; Middle Aged; Neoplasm Staging; Palliative Care; Pneumonectomy; Radiotherapy Dosage; Radiotherapy, Adjuvant; Randomized Controlled Trials as Topic; Taxoids; Time Factors; Topotecan | 2006 |
[Lung cancer with bone metastasis].
Topics: Analgesics; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Camptothecin; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Cisplatin; Combined Modality Therapy; Diphosphonates; Docetaxel; Drug Administration Schedule; Etoposide; Fractures, Bone; Gefitinib; Humans; Irinotecan; Lung Neoplasms; Paclitaxel; Pain, Intractable; Prognosis; Quinazolines; Radiotherapy Dosage; Taxoids | 2006 |
Population pharmacokinetic-pharmacodynamic model for neutropenia with patient subgroup identification: comparison across anticancer drugs.
Topics: Adolescent; Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Agents; Docetaxel; Drug Interactions; Etoposide; Female; Humans; Liver; Male; Middle Aged; Models, Theoretical; Neutropenia; Neutrophils; Paclitaxel; Sex Characteristics; Taxoids; Topotecan | 2006 |
Mediastinal follicular dendritic cell sarcoma involving bone marrow: a case report and review of the literature.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Bone Marrow; Dendritic Cells, Follicular; Deoxycytidine; Docetaxel; Etoposide; Female; Gemcitabine; Humans; Ifosfamide; Immunoenzyme Techniques; Mediastinal Neoplasms; Methotrexate; Middle Aged; Sarcoma; Taxoids; Treatment Outcome | 2006 |
[Outpatient chemotherapy for lung cancer].
Topics: Ambulatory Care; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Cisplatin; Combined Modality Therapy; Deoxycytidine; Docetaxel; Drug Administration Schedule; Etoposide; Gefitinib; Gemcitabine; Humans; Informed Consent; Irinotecan; Lung Neoplasms; Neutropenia; Paclitaxel; Quality of Life; Quinazolines; Taxoids; Vinblastine; Vinorelbine | 2007 |
Methylseleninic acid enhances the effect of etoposide to inhibit prostate cancer growth in vivo.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blotting, Western; Cell Line, Tumor; Cell Proliferation; Docetaxel; Dose-Response Relationship, Drug; Drug Synergism; Etoposide; Gene Expression; Gene Expression Profiling; Humans; Male; Metabolic Networks and Pathways; Mice; Mice, Nude; Oligonucleotide Array Sequence Analysis; Organoselenium Compounds; Prostatic Neoplasms; Reverse Transcriptase Polymerase Chain Reaction; Signal Transduction; Taxoids; Xenograft Model Antitumor Assays | 2007 |
Developmental chemotherapy and management of recurrent ovarian cancer.
Topics: Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Clinical Trials as Topic; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Deoxycytidine; Docetaxel; Doxorubicin; Drugs, Investigational; Enzyme Inhibitors; Etoposide; Female; Gemcitabine; Humans; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Randomized Controlled Trials as Topic; Recurrence; Research Design; Taxoids; Topoisomerase I Inhibitors; Topotecan; Treatment Outcome | 2003 |
Effect of platinum combined with irinotecan or paclitaxel against large cell neuroendocrine carcinoma of the lung.
Topics: Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Large Cell; Carcinoma, Neuroendocrine; Cisplatin; Docetaxel; Etoposide; Female; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Retrospective Studies; Taxoids; Vinblastine; Vinorelbine | 2007 |
Does small-cell phenotype predict the natural history of prostate cancer? A case study in disease behavior.
Topics: Adenocarcinoma; Androgen Antagonists; Anilides; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cisplatin; Docetaxel; Estramustine; Etoposide; Flutamide; Gonadotropin-Releasing Hormone; Humans; Male; Middle Aged; Nephrostomy, Percutaneous; Nitriles; Phenotype; Prostate-Specific Antigen; Prostatic Neoplasms; Taxoids; Tosyl Compounds; Transurethral Resection of Prostate; Urinary Diversion | 2007 |
Dose enhancement effect of anticaner drugs associated with increased temperature in vitro.
Topics: Antineoplastic Agents; Carboplatin; Cell Proliferation; Cell Survival; Combined Modality Therapy; Deoxycytidine; Docetaxel; Dose-Response Relationship, Drug; Doxorubicin; Etoposide; Gemcitabine; HeLa Cells; Humans; Hyperthermia, Induced; Ifosfamide; Organoplatinum Compounds; Oxaliplatin; Taxoids; Temperature; Vinblastine; Vinorelbine | 2008 |
[Effect of neoadjuvant chemotherapy on ERCC1 gene expression in breast cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; DNA-Binding Proteins; Docetaxel; Endonucleases; Etoposide; Female; Gene Expression Regulation, Neoplastic; Humans; Middle Aged; Neoadjuvant Therapy; Reverse Transcriptase Polymerase Chain Reaction; Taxoids | 2008 |
Inhibition of p38 MAPK suppresses inflammatory cytokine induction by etoposide, 5-fluorouracil, and doxorubicin without affecting tumoricidal activity.
Topics: Animals; Antineoplastic Agents; Base Sequence; Cytokines; DNA Primers; Docetaxel; Doxorubicin; Enzyme Activation; Etoposide; Fluorouracil; Inflammation Mediators; Macrophages; Mice; Mice, Inbred C57BL; p38 Mitogen-Activated Protein Kinases; Taxoids | 2008 |
ERCC1 expression as a prognostic marker in N2(+) nonsmall-cell lung cancer patients treated with platinum-based neoadjuvant concurrent chemoradiotherapy.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Cisplatin; Combined Modality Therapy; Disease-Free Survival; DNA-Binding Proteins; Docetaxel; Endonucleases; Etoposide; Female; Humans; Immunoenzyme Techniques; Lung Neoplasms; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Paclitaxel; Survival Rate; Taxoids; Treatment Outcome | 2008 |
Combining carboplatin and etoposide in docetaxel-pretreated patients with castration-resistant prostate cancer: a prospective study evaluating also neuroendocrine features.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Docetaxel; Etoposide; Humans; Male; Middle Aged; Orchiectomy; Prognosis; Prospective Studies; Taxoids; Treatment Outcome | 2009 |
Side effects after docetaxel treatment in Taiwanese breast cancer patients with CYP3A4, CYP3A5, and ABCB1 gene polymorphisms.
Topics: Adult; Alleles; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; Breast Neoplasms; Cyclophosphamide; Cytochrome P-450 CYP3A; Docetaxel; Etoposide; Female; Genotype; Humans; Middle Aged; Polymorphism, Single Nucleotide; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Taxoids | 2009 |
Limited inter-occasion variability in relation to inter-individual variability in chemotherapy-induced myelosuppression.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Cell Count; Cell Enlargement; Cell Proliferation; Docetaxel; Dose-Response Relationship, Drug; Epirubicin; Etoposide; Fluorouracil; Humans; Models, Biological; Myelopoiesis; Neoplasms; Neutrophils; Observation; Paclitaxel; Precision Medicine; Taxoids; Topotecan | 2010 |
Clinical significance of Ki-67 in neoadjuvant chemotherapy for primary breast cancer as a predictor for chemosensitivity and for prognosis.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Biomarkers; Breast Neoplasms; Cell Proliferation; Cyclophosphamide; Docetaxel; Drug Resistance, Neoplasm; Epirubicin; Etoposide; Female; Fluorouracil; Humans; Ki-67 Antigen; Logistic Models; Middle Aged; Multivariate Analysis; Neoadjuvant Therapy; Prognosis; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Retrospective Studies; Survival Analysis; Tamoxifen; Taxoids; Tumor Suppressor Protein p53 | 2010 |
Docetaxel combined with oral etoposide as second-line treatment for advanced gastric carcinoma after failure of platinum- and fluoropyrimidine-based regimens.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetaxel; Etoposide; Female; Fluorouracil; Humans; Infusions, Intravenous; Male; Middle Aged; Neoplasm Metastasis; Retrospective Studies; Stomach Neoplasms; Taxoids; Treatment Failure | 2010 |
Deubiquitinase USP9X stabilizes MCL1 and promotes tumour cell survival.
Topics: Animals; Apoptosis; Biphenyl Compounds; Cell Line; Cell Line, Tumor; Cell Survival; DNA Damage; Docetaxel; Etoposide; Female; Gene Expression Regulation, Neoplastic; Gene Knockdown Techniques; Half-Life; Humans; Lysine; Mice; Mice, SCID; Myeloid Cell Leukemia Sequence 1 Protein; Neoplasms; Nitrophenols; Phosphorylation; Piperazines; Polyubiquitin; Prognosis; Protein Binding; Protein Stability; Proto-Oncogene Proteins c-bcl-2; RNA Interference; Sulfonamides; Taxoids; Ubiquitin Thiolesterase; Ubiquitination; Ultraviolet Rays; Xenograft Model Antitumor Assays | 2010 |
Adjuvant oral etoposide plus cisplatin (EoP) following sequential doxorubicin/cyclophosphamide (AC) and docetaxel (T) in early breast cancer patients with 4 or more positive lymph nodes (10 years follow-up).
Topics: Administration, Oral; Antibiotics, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cisplatin; Cyclophosphamide; Disease-Free Survival; Docetaxel; Doxorubicin; Drug Administration Schedule; Etoposide; Female; Follow-Up Studies; Humans; Kaplan-Meier Estimate; Lymphatic Metastasis; Middle Aged; Pilot Projects; Taxoids | 2011 |
A retrospective analysis of non-platinum-based first- and second-line chemotherapy in patients with advanced non-small cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Docetaxel; Etoposide; Female; Gemcitabine; Glutamates; Guanine; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Pemetrexed; Piperidines; Quinazolines; Retrospective Studies; Taxoids; Treatment Outcome; Vinblastine; Vinorelbine | 2010 |
Permanent alopecia after systemic chemotherapy: a clinicopathological study of 10 cases.
Topics: Alopecia; Antineoplastic Agents; Busulfan; Cisplatin; Dermis; Diagnosis, Differential; Docetaxel; Etoposide; Female; Hair; Humans; Male; Neoplasms; Taxoids | 2011 |
Hypersensitivity reactions to anticancer agents: data mining of the public version of the FDA adverse event reporting system, AERS.
Topics: Adverse Drug Reaction Reporting Systems; Antineoplastic Agents; Asparaginase; Bayes Theorem; Data Mining; Docetaxel; Drug Hypersensitivity; Etoposide; Humans; Paclitaxel; Pharmacovigilance; Procarbazine; Prognosis; Taxoids; Teniposide; United States; United States Food and Drug Administration | 2011 |
Liposomal formulations of Etoposide and Docetaxel for p53 mediated enhanced cytotoxicity in lung cancer cell lines.
Topics: Annexin A5; beta-Galactosidase; Cell Death; Cell Line, Tumor; Chemistry, Pharmaceutical; Coumarins; Deoxyribonucleases; Docetaxel; Electrophoresis, Agar Gel; Electrophoretic Mobility Shift Assay; Etoposide; Flow Cytometry; Fluorescein-5-isothiocyanate; Freeze Drying; Humans; Intracellular Space; Liposomes; Lung Neoplasms; Microscopy, Electron, Transmission; Particle Size; Static Electricity; Taxoids; Transfection; Tumor Suppressor Protein p53 | 2012 |
Routine administration of a single dose of cisplatin ≥ 75 mg/m2 after short hydration in an outpatient lung-cancer clinic.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Creatinine; Deoxycytidine; Docetaxel; Etoposide; Female; Fluid Therapy; Gemcitabine; Humans; Kidney; Kidney Diseases; Lung Neoplasms; Male; Middle Aged; Retrospective Studies; Small Cell Lung Carcinoma; Taxoids; Vinblastine; Vinorelbine | 2012 |
Synergistic combinations of multiple chemotherapeutic agents in high capacity poly(2-oxazoline) micelles.
Topics: Antineoplastic Agents; Benzoquinones; Cell Line, Tumor; Cell Survival; Docetaxel; Drug Carriers; Drug Delivery Systems; Etoposide; Hep G2 Cells; Humans; Lactams, Macrocyclic; Micelles; Oxazoles; Taxoids | 2012 |
Normal serum CA125 half-life and normal serum nadir CA125 level in patients with ovarian cancers.
Topics: Adult; Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; CA-125 Antigen; Camptothecin; Carboplatin; Carcinoma, Ovarian Epithelial; Cisplatin; Cyclophosphamide; Docetaxel; Doxorubicin; Etoposide; Female; Half-Life; Humans; Irinotecan; Linear Models; Middle Aged; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Reference Values; Remission Induction; Taxoids | 2012 |
[Sensitivity to chemotherapeutic drugs of polyploid tumor cells induced by a spindle poison nocodazole].
Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Apoptosis; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Docetaxel; Down-Regulation; Drug Resistance, Neoplasm; Epirubicin; Etoposide; Female; Fluorouracil; Gene Knockdown Techniques; Humans; Inhibitory Concentration 50; Nocodazole; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Polyploidy; Proto-Oncogene Proteins c-bcl-2; RNA, Messenger; RNA, Small Interfering; Taxoids; Vincristine | 2012 |
Characterization of the low pH/low nutrient-resistant LNCaP cell subline LNCaP-F10.
Topics: Animals; Antineoplastic Agents; Apoptosis; Apoptosis Regulatory Proteins; Calcium-Calmodulin-Dependent Protein Kinases; Cell Line, Tumor; Cell Proliferation; Death-Associated Protein Kinases; DNA Fragmentation; Docetaxel; Etoposide; Gene Expression Regulation, Neoplastic; Humans; Hydrogen-Ion Concentration; Inhibitor of Apoptosis Proteins; Male; Mice; Mice, Nude; Neoplasm Transplantation; Paclitaxel; Poly(ADP-ribose) Polymerases; Prostatic Neoplasms; Proto-Oncogene Proteins c-bcl-2; Survivin; Taxoids; Transplantation, Heterologous | 2012 |
Pathological complete response and two-year disease-free survival in a primary gastric choriocarcinoma patient with advanced liver metastases treated with germ cell tumor-based chemotherapy: a case report.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Choriocarcinoma, Non-gestational; Chorionic Gonadotropin, beta Subunit, Human; Cisplatin; Disease-Free Survival; Docetaxel; Etoposide; Fluorouracil; Humans; Liver Neoplasms; Male; Neoplasm, Residual; Stomach Neoplasms; Survival Analysis; Taxoids | 2012 |
New advances in the treatment of gastric cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemoradiotherapy, Adjuvant; Chemotherapy, Adjuvant; Cisplatin; Deoxycytidine; Docetaxel; Doxorubicin; Drug Combinations; Etoposide; Fluorouracil; Humans; Leucovorin; Levoleucovorin; Methotrexate; Organoplatinum Compounds; Oxonic Acid; Stomach Neoplasms; Taxoids; Tegafur | 2004 |
[Analysis of drug therapy of lung cancer in Hungary].
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Chemotherapy, Adjuvant; Cisplatin; Databases, Factual; Deoxycytidine; Docetaxel; Drug Administration Schedule; Erlotinib Hydrochloride; Etoposide; Gemcitabine; Glutamates; Guanine; Humans; Hungary; Inpatients; Insurance, Health; Lung Neoplasms; Paclitaxel; Pemetrexed; Prescription Drugs; Quinazolines; Retrospective Studies; Taxoids; Topotecan | 2013 |
Increased chemosensitivity via targeting testicular nuclear receptor 4 (TR4)-Oct4-interleukin 1 receptor antagonist (IL1Ra) axis in prostate cancer CD133+ stem/progenitor cells to battle prostate cancer.
Topics: AC133 Antigen; Antigens, CD; Antineoplastic Agents, Phytogenic; Cell Line, Tumor; Docetaxel; Drug Resistance, Neoplasm; Etoposide; Gene Expression Regulation, Neoplastic; Gene Knockdown Techniques; Glycoproteins; Humans; Interleukin 1 Receptor Antagonist Protein; Male; Neoplastic Stem Cells; Octamer Transcription Factor-3; Peptides; Prostatic Neoplasms; Receptors, Steroid; Receptors, Thyroid Hormone; Taxoids | 2013 |
Sequential chemotherapies for advanced gastric cancer: a retrospective analysis of 111 patients.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Deoxycytidine; Docetaxel; Drug Administration Schedule; Epirubicin; Etoposide; Female; Fluorouracil; Gemcitabine; Germany; Hospitals, University; Humans; Irinotecan; Kaplan-Meier Estimate; Leucovorin; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Prognosis; Retrospective Studies; Salvage Therapy; Stomach Neoplasms; Taxoids; Treatment Outcome | 2013 |
[Salvage therapy for castration-refractory prostate cancer resistant to docetaxel].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Clinical Trials as Topic; Cyclophosphamide; Docetaxel; Drug Combinations; Drug Resistance, Neoplasm; Etoposide; Humans; Male; Middle Aged; Oxonic Acid; Paclitaxel; Prostatic Neoplasms, Castration-Resistant; Salvage Therapy; Streptonigrin; Taxoids; Tegafur; Uracil | 2013 |
Cisplatin versus carboplatin-based regimens for the treatment of patients with metastatic lung cancer. An analysis of Veterans Health Administration data.
Topics: Aged; Ambulatory Care; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Docetaxel; Etoposide; Female; Gemcitabine; Glutamates; Guanine; Hospitalization; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Pemetrexed; Registries; Retrospective Studies; Survival Rate; Taxoids; United States; United States Department of Veterans Affairs; Vinblastine; Vinorelbine | 2014 |
Hypersensitivity to chemotherapeutics: a cross sectional study with 35 desensitisations.
Topics: Adult; Aged; Antineoplastic Agents; Carboplatin; Cross-Sectional Studies; Desensitization, Immunologic; Docetaxel; Drug Eruptions; Etoposide; Female; Humans; Hypersensitivity, Delayed; Hypersensitivity, Immediate; Lung Neoplasms; Male; Middle Aged; Pemetrexed; Skin Tests; Taxoids | 2015 |
Outcomes of immediate perforator flap reconstruction after skin-sparing mastectomy following neoadjuvant chemotherapy.
Topics: Adult; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Carcinoma, Ductal, Breast; Carcinoma, Intraductal, Noninfiltrating; Carcinoma, Lobular; Chemotherapy, Adjuvant; Cohort Studies; Cyclophosphamide; Docetaxel; Epirubicin; Etoposide; Female; Fluorouracil; Humans; Mammaplasty; Mastectomy, Subcutaneous; Middle Aged; Neoadjuvant Therapy; Paclitaxel; Perforator Flap; Retrospective Studies; Taxoids; Trastuzumab; Treatment Outcome; Young Adult | 2015 |
Dose schedule optimization and the pharmacokinetic driver of neutropenia.
Topics: Animals; Antineoplastic Agents; Docetaxel; Drug Administration Schedule; Etoposide; Humans; Male; Models, Biological; Models, Theoretical; Neutropenia; Rats, Sprague-Dawley; Taxoids; Topotecan | 2014 |
A Pilot Trial of Cisplatin/Etoposide/Radiotherapy Followed by Consolidation Docetaxel and the Combination of Bevacizumab (NSC-704865) in Patients With Inoperable Locally Advanced Stage III Non-Small-Cell Lung Cancer: SWOG S0533.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Cisplatin; Cohort Studies; Combined Modality Therapy; Docetaxel; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Pilot Projects; Taxoids | 2015 |
Use of Adjuvant Cisplatin-Based Versus Carboplatin-Based Chemotherapy in Non-Small-Cell Lung Cancer: Findings From the Florida Initiative for Quality Cancer Care.
Topics: Academic Medical Centers; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Cisplatin; Deoxycytidine; Docetaxel; Etoposide; Female; Florida; Gemcitabine; Humans; Lung Neoplasms; Male; Medical Audit; Middle Aged; Paclitaxel; Pneumonectomy; Practice Patterns, Physicians'; Quality of Health Care; Taxoids; Time Factors; Vinblastine; Vinorelbine | 2015 |
Circulating endothelial cells for evaluation of tumor response in non-small cell lung cancer patients receiving first-line chemotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Case-Control Studies; Cisplatin; Deoxycytidine; Disease-Free Survival; Docetaxel; Endothelial Cells; Etoposide; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Neoplastic Cells, Circulating; Neovascularization, Pathologic; Paclitaxel; Prospective Studies; Taxoids; Treatment Outcome; Vinblastine; Vinorelbine | 2015 |
Effects of Chemotherapy Regimen and Radiation Modality on Hematologic Toxicities in Patients Receiving Definitive Platinum-based Doublet Chemoradiation for Non-Small Cell Lung Cancer.
Topics: Adult; Aged; Aged, 80 and over; Anemia; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Chemoradiotherapy; Cisplatin; Docetaxel; Etoposide; Female; Hemoglobins; Humans; Leukopenia; Logistic Models; Lung Neoplasms; Lymphopenia; Male; Middle Aged; Multivariate Analysis; Neoplasm Staging; Neutropenia; Paclitaxel; Proportional Hazards Models; Radiation Injuries; Radiotherapy, Conformal; Radiotherapy, Intensity-Modulated; Retrospective Studies; Severity of Illness Index; Survival Rate; Taxoids; Thrombocytopenia | 2017 |
Genome-Wide Identification and Characterization of Novel Factors Conferring Resistance to Topoisomerase II Poisons in Cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis Regulatory Proteins; Capecitabine; Carcinoma; Chromosomal Proteins, Non-Histone; CRISPR-Cas Systems; Cyclophosphamide; DNA Helicases; DNA-Binding Proteins; Docetaxel; Doxorubicin; Drug Resistance, Neoplasm; Etoposide; Female; Gene Expression Profiling; Genome-Wide Association Study; Humans; Intracellular Signaling Peptides and Proteins; Kelch-Like ECH-Associated Protein 1; Neoplasm Proteins; Nuclear Proteins; RNA Interference; RNA, Small Interfering; Sarcoma; SMARCB1 Protein; Taxoids; Topoisomerase II Inhibitors; Topotecan; Transcription Factors; Triple Negative Breast Neoplasms | 2015 |
Comparison of efficacy and safety of three different chemotherapy regimens delivered with concomitant radiotherapy in inoperable stage III non-small cell lung cancer patients.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Combined Modality Therapy; Disease-Free Survival; Docetaxel; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Radiotherapy Dosage; Retrospective Studies; Taxoids | 2016 |
Concomitant etoposide and cisplatin provided improved survival compared with docetaxel and cisplatin in patients with locally advanced non-small cell lung cancer treated with chemoradiotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Chemoradiotherapy; Cisplatin; Docetaxel; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Retrospective Studies; Survival Rate; Taxoids; Treatment Outcome | 2016 |
Antitumor effect of Deoxypodophyllotoxin on human breast cancer xenograft transplanted in BALB/c nude mice model.
Topics: 2-Hydroxypropyl-beta-cyclodextrin; Administration, Intravenous; Animals; Antineoplastic Agents, Phytogenic; beta-Cyclodextrins; Breast Neoplasms; Cell Line, Tumor; Docetaxel; Drugs, Chinese Herbal; Etoposide; Female; Humans; Mice; Mice, Inbred BALB C; Mice, Nude; Podophyllotoxin; Taxoids; Xenograft Model Antitumor Assays | 2016 |
Development of symptomatic brain metastases after chemoradiotherapy for stage III non-small cell lung cancer: Does the type of chemotherapy regimen matter?
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Brain; Brain Neoplasms; Bridged-Ring Compounds; Carcinoma, Non-Small-Cell Lung; Chemoradiotherapy; Cisplatin; Combined Modality Therapy; Docetaxel; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Retrospective Studies; Risk Factors; Survival Analysis; Taxoids; Treatment Outcome; Vinblastine; Vinorelbine | 2016 |
Chemotherapy for pulmonary large cell neuroendocrine carcinomas: does the regimen matter?
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Carcinoma, Large Cell; Carcinoma, Neuroendocrine; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Docetaxel; Etoposide; Female; Gemcitabine; Humans; Male; Middle Aged; Netherlands; Paclitaxel; Pemetrexed; Registries; Small Cell Lung Carcinoma; Taxoids; Vinblastine; Vinorelbine | 2017 |
Lung Cancer with a Small Cell Carcinoma Component Diagnosed from Pleural Effusion and a Squamous Cell Carcinoma Component Diagnosed from the Tumor.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biopsy, Needle; Carboplatin; Carcinoma, Squamous Cell; Docetaxel; Etoposide; Humans; Immunohistochemistry; Lung Neoplasms; Male; Pleural Effusion, Malignant; Small Cell Lung Carcinoma | 2018 |
Targeting of TMPRSS4 sensitizes lung cancer cells to chemotherapy by impairing the proliferation machinery.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Cisplatin; Docetaxel; Etoposide; Fluorouracil; HEK293 Cells; Humans; Lung Neoplasms; Membrane Proteins; Methotrexate; Mice; Molecular Targeted Therapy; Pemetrexed; Serine Endopeptidases | 2019 |
Real-world treatment patterns and outcomes of patients with extensive disease small cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Comorbidity; Cyclophosphamide; Deprescriptions; Docetaxel; Doxorubicin; Drug Tapering; Etoposide; Female; Functional Status; Humans; Lung Neoplasms; Male; Middle Aged; Netherlands; Paclitaxel; Practice Patterns, Physicians'; Progression-Free Survival; Retrospective Studies; Small Cell Lung Carcinoma; Survival Rate; Topotecan | 2020 |
Comparison of three different chemotherapy regimens for concomitant chemoradiotherapy in locally advanced non-small cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Chemoradiotherapy; Docetaxel; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Retrospective Studies; Survival Analysis; Treatment Outcome | 2020 |
Evaluation of ovarian reserve before and after chemotherapy.
Topics: Adolescent; Adult; Anti-Mullerian Hormone; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Breast Neoplasms; Cyclophosphamide; Dacarbazine; Docetaxel; Doxorubicin; Epirubicin; Etoposide; Female; Fertility Preservation; Fluorouracil; Hodgkin Disease; Humans; Longitudinal Studies; Luminescent Measurements; Ovarian Reserve; Prednisone; Procarbazine; Vinblastine; Vincristine; Young Adult | 2021 |
The Circadian Protein PER1 Modulates the Cellular Response to Anticancer Treatments.
Topics: A549 Cells; Animals; Antineoplastic Agents; Apoptosis; Carcinogenesis; Cell Cycle; Cell Line, Tumor; Circadian Rhythm; Cisplatin; Docetaxel; Drug Chronotherapy; Etoposide; Humans; Mice; Neoplasms; Period Circadian Proteins; Tumor Suppressor Protein p53; Xenograft Model Antitumor Assays | 2021 |
DNA-PKc inhibition overcomes taxane resistance by promoting taxane-induced DNA damage in prostate cancer cells.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Survival; Chromones; DNA Damage; DNA-Activated Protein Kinase; Docetaxel; Drug Resistance, Neoplasm; Etoposide; Humans; Male; Morpholines; Prostatic Neoplasms; Protein Kinase Inhibitors; Pyridazines; Quinazolines; Taxoids | 2021 |
Self-emulsifying Drug Delivery System for Oral Anticancer Therapy: Constraints and Recent Development.
Topics: Administration, Oral; Antineoplastic Agents; Biological Availability; Chemistry, Pharmaceutical; Docetaxel; Doxorubicin; Drug Delivery Systems; Emulsions; Etoposide; Fluorouracil; Humans; Paclitaxel; Solubility; Surface-Active Agents | 2022 |
Development and application of a liquid chromatography coupled to mass spectrometry method for the simultaneous determination of 23 antineoplastic drugs at trace levels.
Topics: Antineoplastic Agents; Busulfan; Carboplatin; Chromatography, Liquid; Cyclophosphamide; Cytarabine; Dacarbazine; Daunorubicin; Docetaxel; Doxorubicin; Epirubicin; Etoposide; Fluorouracil; Ganciclovir; Humans; Idarubicin; Ifosfamide; Irinotecan; Methanol; Methotrexate; Oxaliplatin; Paclitaxel; Pemetrexed; Tandem Mass Spectrometry; Topotecan; Vinblastine; Vincristine; Water | 2022 |
Comparison of permeabilities of eight different types of cytotoxic drugs to five gloves with different materials by LC-MS/MS methods to reduce occupational exposure of medical personnel.
Topics: Antineoplastic Agents; Chromatography, Liquid; Cisplatin; Docetaxel; Etoposide; Fluorouracil; Gloves, Protective; Humans; Occupational Exposure; Permeability; Polyethylenes; Rubber; Tandem Mass Spectrometry | 2023 |